AC Immune S.A. (ACIU) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low9.1·High9.1
P/FCF
N/A
—
5yr avg: 4.12
30Y Low4.1·High11.4
P/B Ratio
↑
4.35
↑+48% vs avg
5yr avg: 2.94
30Y Low1.0·High7.0
ROE
↓
-89.6%
↑-97% vs avg
5yr avg: -45.6%
30Y Low-286%·High78%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACIU Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AC Immune S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $244M | $316M | $269M | $423M | $170M | $371M | $372M | $606M | $584M | $734M | $650M |
| Enterprise Value | $217M | $294M | $238M | $348M | $142M | $292M | $213M | $415M | $428M | $610M | $498M |
| P/E Ratio → | -2.77 | — | — | — | — | — | — | 13.31 | — | — | — |
| P/S Ratio | 55.30 | 88.54 | 9.86 | 28.61 | 43.32 | — | 24.09 | 5.48 | 81.23 | 36.25 | 28.01 |
| P/B Ratio | 4.35 | 7.04 | 2.40 | 2.64 | 1.01 | 1.60 | 1.73 | 2.22 | 3.29 | 6.28 | 4.57 |
| P/FCF | — | — | 4.12 | — | — | — | — | 11.36 | — | — | — |
| P/OCF | — | — | 4.09 | — | — | — | — | 10.97 | — | — | — |
P/E links to full P/E history page with 30-year chart
ACIU EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 82.31 | 8.73 | 23.54 | 36.00 | — | 13.81 | 3.76 | 59.55 | 30.12 | 21.45 |
| EV / EBITDA | — | — | — | — | — | — | — | 9.06 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 9.32 | — | — | — |
| EV / FCF | — | — | 3.65 | — | — | — | — | 7.78 | — | — | — |
ACIU Profitability
Margins and return-on-capital ratios measuring operating efficiency
AC Immune S.A. earns an operating margin of -1927.3%. Operating margins have compressed from -362.3% to -1927.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -89.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -129.1% | -268.9% | 100.0% | — | -285.5% | 54.3% | -515.5% | -61.3% | -11.0% |
| Operating Margin | -1927.3% | -1927.3% | -191.8% | -362.3% | -1800.4% | — | -397.0% | 40.3% | -688.8% | -111.3% | -45.0% |
| Net Profit Margin | -1971.6% | -1971.6% | -186.4% | -366.4% | -1798.0% | — | -401.3% | 41.1% | -708.2% | -130.4% | -30.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -89.6% | -89.6% | -37.3% | -32.9% | -35.3% | -32.6% | -25.4% | 20.2% | -34.6% | -20.4% | -6.6% |
| ROA | -36.6% | -36.6% | -24.6% | -29.4% | -31.6% | -29.2% | -23.0% | 18.3% | -31.0% | -18.3% | -6.0% |
| ROIC | -99.2% | -99.2% | -47.0% | -35.6% | -36.3% | -56.6% | -66.3% | 64.6% | -511.3% | — | — |
| ROCE | -72.6% | -72.6% | -35.0% | -31.2% | -34.1% | -33.9% | -24.2% | 19.1% | -32.4% | -16.8% | -9.5% |
ACIU Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $27M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.05 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.06 | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.27 | -0.47 | -0.17 | -0.34 | -0.74 | -0.70 | -0.88 | -1.06 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -4.16 | — | — | — |
| Debt / FCF | — | — | -0.47 | — | — | — | — | -3.58 | — | — | — |
| Interest Coverage | -367.83 | -367.83 | -381.80 | -307.09 | -198.27 | -124.63 | -332.93 | 23.12 | -151.55 | -178.67 | -27.69 |
Net cash position: cash ($27M) exceeds total debt ($5M)
ACIU Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.02x means AC Immune S.A. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 9.22x to 1.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | 1.02 | 1.71 | 9.22 | 11.16 | 10.12 | 16.53 | 16.72 | 14.75 | 13.28 | 15.61 |
| Quick Ratio | 1.02 | 1.02 | 1.71 | 9.22 | 11.16 | 10.12 | 16.53 | 16.72 | 14.75 | 13.42 | 15.57 |
| Cash Ratio | 0.97 | 0.97 | 1.64 | 7.59 | 10.68 | 9.90 | 16.11 | 16.48 | 14.25 | 12.75 | 15.34 |
| Asset Turnover | — | 0.02 | 0.12 | 0.08 | 0.02 | — | 0.06 | 0.37 | 0.04 | 0.15 | 0.15 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 66.26 |
| Days Sales Outstanding | — | 69.65 | 14.69 | 371.04 | 37.84 | — | 37.63 | 4.62 | 208.12 | 66.98 | 22.11 |
ACIU Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AC Immune S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 7.5% | — | — | — |
| FCF Yield | — | — | 24.2% | — | — | — | — | 8.8% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $101M | $100M | $85M | $84M | $75M | $72M | $71M | $62M | $57M | $50M |
Peer Comparison
Compare ACIU with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACIUYou | $244M | -2.8 | — | — | 100.0% | -1927.3% | -89.6% | -99.2% | — |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 ANVS | $34M | -1.3 | — | — | — | — | -220.6% | — | — |
 NRXP | $69M | -3.0 | — | — | 58.8% | -1324.4% | — | — | — |
 BIIB | $29B | 22.3 | 11.7 | 14.2 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 LLY | $1.0T | 47.8 | 34.3 | 115.6 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PRTA | $468M | -2.0 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ACIU — Frequently Asked Questions
Quick answers to the most common questions about buying ACIU stock.
What is AC Immune S.A.'s P/E ratio?
AC Immune S.A.'s current P/E ratio is -2.8x. The historical average is 13.3x.
What is AC Immune S.A.'s ROE?
AC Immune S.A.'s return on equity (ROE) is -89.6%. The historical average is -35.3%.
Is ACIU stock overvalued?
Based on historical data, AC Immune S.A. is trading at a P/E of -2.8x. Compare with industry peers and growth rates for a complete picture.
What are AC Immune S.A.'s profit margins?
AC Immune S.A. has 100.0% gross margin and -1927.3% operating margin.